成年患者的MEK抑制 皮洛细胞性星系细胞瘤
Konstantinos Rounis1,2, Anna Falk Delgado3,4, Christopher Illies5
1Karolinska Comprehensive Cancer Center, Solna, Sweden. konstantinos.rounis@ki.se.
NPJ precision oncology
|March 17, 2026
概括
中原激活蛋白激酶抑制剂 (MEK) 对成年皮洛细胞性星细胞瘤 (PAs) 的治疗有前途. 这项研究发现,特拉美丁尼在成人PA患者中有效,观察到部分反应和稳定的疾病.
科学领域:
- 神经瘤学神经瘤学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 皮洛细胞性星瘤 (PAs) 是一种罕见的原发性脑瘤,在成年人中与儿童相比,其结果较差.
- 目前的手术和放射治疗 (RT) 等治疗方法都有局限性,包括毒性.
- 酸酶通常显示出基因激活蛋白激酶 (MAPK) 途径的激活.
研究的目的:
- 评估Trametinib,一种MEK1/2抑制剂的疗效,在患有皮洛细胞性星细胞瘤的成年患者中.
- 在这个患者队列中评估治疗结果和无进展生存率.
主要方法:
- 对五名成年患者 (30-79岁) 进行了回顾性分析,这些患者患有皮洛细胞性星细胞瘤或形转变.
- 患者接受了MEK1/2抑制剂特拉美丁尼布.
- 对NF-1突变进行了瘤遗传分析.
主要成果:
- 根据RANO 2.0标准,有3名患者实现了部分反应,有2名患者的病情稳定.
- 两名患者的神经状况有所改善.
- 无进展生存时间的中位数为16.65个月.
结论:
- 用特拉梅丁尼布抑制MEK代表了成人皮洛细胞性星细胞瘤的潜在有效治疗策略.
- 需要进一步的研究来证实这些发现在更大的成年人群中.
相关概念视频
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...


